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Running Title:  Ipilimumab and Nivolumab in Rare Tumors S1609:Neuroendocrine
Statement of Translational Relevance:  SWOG DART S1609 is the first study of 
combination anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab) across rare 
tumors, with this cohort focusing on non-pancreatic neuroendocrine neoplasms.  
Patients with high-grade neuroendocrine carcinoma had a 44% objective response 
rate (ORR), which could be driven by anti-CTLA-4 in the therapeutic combination in 
this high tumor mutational burden (TMB) subgroup.   Central pathology review, PD-
L1 status, and TMB were not available for enrolled patients.
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Abstract:
Purpose:  Immune checkpoint blockade has improved outcomes across tumor 
types; little is known about the efficacy of these agents in rare tumors.   We report 
the results of the (non-pancreatic) neuroendocrine neoplasm cohort of SWOG 
S1609 Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors (DART).
Experimental Design:  We performed a prospective, open-label, multicenter 
phase 2 clinical trial of ipilimumab plus nivolumab across multiple rare tumor 
cohorts, with the (non-pancreatic) neuroendocrine cohort reported here.  Response 
assessment by grade was not pre-specified.  The primary endpoint was overall 
response rate (ORR) (RECIST v1.1) (complete response (CR) and partial response 
(PR)); secondary endpoints included progression-free survival (PFS), overall survival
(OS), stable disease >6 months, and toxicity.
Results:   Thirty-two eligible patients received therapy; 18 (56%) had high-grade 
disease.  Most common primary sites were gastrointestinal (47%; N= 15) and lung 
(19%; N= 6).  The overall ORR was 25% (95% confidence interval (CI) 13-64%; CR, 
3%, N= 1; PR, 22%, N= 7).  Patients with high-grade neuroendocrine carcinoma had
an ORR of 44% (8/18 patients) versus 0% in low/intermediate grade tumors (0/14 
patients) (p=0.004). The 6-month PFS was 31% (95% CI 19-52%); median OS was 
11 months (95% CI 6-∞).  The most common toxicities were hypothyroidism (31%), 
fatigue (28%), and nausea (28%); with alanine aminotransferase (ALT) elevation 
(9%) as the most common grade 3/4 immune-related adverse event, and no grade 
5 events.  
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Conclusions:   Ipilimumab plus nivolumab demonstrated a 44% ORR in patients 
with non-pancreatic high-grade neuroendocrine carcinoma, with 0% ORR in 
low/intermediate grade disease.
Trial Registration:  ClinicalTrials.gov registry:  NCT02834013
Keywords:  neuroendocrine carcinoma, rare tumors, S1609, DART, ipilimumab, 
nivolumab
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INTRODUCTION
Immune checkpoint blockade has transformed oncology with the potential for 
durable responses even in patients with metastatic disease.  Approved indications 
for immune checkpoint blockade in rare tumors are limited to Merkel cell 
carcinoma, cutaneous squamous cancers, and microsatellite-unstable malignancies
(1).  Rare cancer histologies, collectively representing approximately a quarter of all
cancers diagnosed, remain understudied and the efficacy of immune checkpoint 
blockade in these patient populations is unknown.  
Neuroendocrine neoplasms represent a rare histologic subset of tumors with 
complex classification criteria dependent on the putative organ of origin, precluding
a single taxonomy across anatomic sites (2).  The World Health Organization (WHO)
and European Neuroendocrine Tumour Society (ENETS) have developed a 
classification scheme reflected in the most recent staging guidelines (Appendix 
Table 1) and was utilized in our study.  Neuroendocrine neoplasms can develop 
throughout the body, with pancreatic neuroendocrine tumors (PNET) in particular 
having unique biological and clinical characteristics resulting in additional therapies
being utilized for PNETs. Thus, PNETs are assessed in a separate cohort within 
S1609, currently accruing.  Clinical trials for neuroendocrine neoplasms, particularly
in high-grade neuroendocrine carcinomas, have been difficult to conduct due to the 
rarity of the disease, difficulties in precise classification, and a lack of robust 
predictive biomarkers for therapeutic efficacy.  In this study we evaluated the 
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combination of ipilimumab and nivolumab in patients with diverse histologic sites 
and across tumor grades.
SWOG 1609 DART (Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors), a 
basket immunotherapy trial studying ipilimumab plus nivolumab across multiple 
cohorts of rare tumor histologic subtypes, was designed to address the question of 
the efficacy of these agents in these understudied populations.  The combination of 
ipilimumab and nivolumab was selected over nivolumab alone due to the signal-
finding nature of this study with small cohorts of rare tumors, with lower-dose 
ipilimumab chosen to balance tolerability with potential efficacy.  The trial is 
currently open across the United States at 861 sites.  We present here the clinical 
data of the (non-pancreatic) neuroendocrine cohort of SWOG 1609 (S1609) DART.  
PATIENTS AND METHODS 
The trial was conducted by SWOG, and the investigational agents were 
provided by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer 
Institute (NCI) under an NCI CRADA agreement with Bristol-Myers Squibb (BMS).  All
study subjects provided their voluntary, written informed consent using a document
approved by the institution’s human subject protection committee.  The study was 
conducted in accordance with the Declaration of Helsinki.  The protocol and all 
amendments were approved by SWOG, the NCI, the NCI central institutional review 
board (CIRB), and by the regulatory committees at the participating institutions.  
The Caris analysis of neuroendocrine specimens is IRB exempt as all data were 
analyzed utilizing de-identified aggregate data.
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Rationale for Population:
Rare cancers, for the purposes of this study, were identified typically with an 
incidence of less than 6 in 100,000 per year (3).  Tumor grading was based on 2010
WHO criteria, pathology and grade were determined by review of local pathology 
reports by the study principal investigators.  No central pathology review was 
performed.  This cohort (Cohort 23) of S1609 is comprised of refractory 
neuroendocrine neoplasms, independent of histologic grade and organ of origin, 
with the exception of pancreatic neuroendocrine neoplasms, which were stratified 
to a different cohort due to unique biology and alternate standard of care therapies.
Well-differentiated, grade 3 neuroendocrine neoplasms were eligible for this cohort,
and  microsatellite instability (MSI) status was not available.
Patient Selection:
Eligible patients had (non-pancreatic) neuroendocrine neoplasms, had 
progressed following at least one line of standard systemic therapy, and did not 
have an approved or standard therapy available that had been shown to prolong 
overall survival.  At enrollment, patients were required to be 18 years of age or 
older, have a Zubrod performance status of 0-2, adequate hematologic, hepatic, 
thyroid, adrenal axis, and renal function, with absolute neutrophil count ≥ 
1,000/mcL, platelets ≥ 75,000/mcL, hemoglobin ≥ 8 g/dL, creatinine clearance ≥ 
50 mL/min, total bilirubin ≤ 2.0 x institutional upper limit of normal (IULN), AST and 
ALT ≤ 3.0 x IULN, TSH or free T4 serum ≤ IULN, and normal adrenocorticotropic 
hormone (ACTH) ≤ IULN.  Women of childbearing potential were required to have a 
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negative serum pregnancy test, and subjects were required to practice adequate 
birth control during protocol participation.  
Treatment and Monitoring:
Treatment consisted of nivolumab 240mg intravenously (IV) every 2 weeks 
and ipilimumab 1mg/kg IV every 6 weeks on a continuous schedule, with dose 
adjustments and brief breaks from therapy specified in the protocol for treatment-
related toxicities. Patients were removed from study therapy for disease 
progression, symptomatic deterioration, treatment delay for any reason >56 days, 
unacceptable or immune-related toxicity with inability to decrease prednisone to < 
10mg daily, or per patient request. 
Patients were evaluated with a history and physical, laboratory analyses 
(complete blood count, comprehensive metabolic panel, thyroid stimulating 
hormone, free thyroxine, ACTH, cortisol, lipase), and toxicity assessment at least 
every 6 weeks at the beginning of each cycle.  Imaging studies for disease 
assessment were performed pre-study, week 8, week 16, week 24, and then every 
12 weeks until progression.  
Statistical  Methods and Outcomes:  
The primary objective of this Phase II trial was to evaluate the overall 
response rate (ORR, confirmed complete and partial responses [CR and PR]) by 
RECIST v1.1 based on local site review. Our objective was to distinguish between a 
true ORR ≤5% (null hypothesis, as patients had failed all known active therapies) 
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versus ≥ 30% (alternative hypothesis, a potentially clinically meaningful difference 
in tumor response in refractory solid tumors). A Simon’s two-stage design was used,
which required an analysis on the first 6 eligible patients who received protocol 
therapy. If 1 or more of the 6 patients had a response (confirmed CR or PR), an 
additional 10 patients were to be accrued. The design specified 2 or more 
responses out of 16 patients would reject the null hypothesis (one-sided alpha = 
13%, power = 87%).  This cohort accrued more than 16 patients because, 
unexpectedly, accrual was faster than expected following the two-week closure 
notification and several additional patients were enrolled onto incorrect cohorts in 
S1609 and re-stratified into this cohort after SWOG review of local pathology 
reports prior to knowledge of clinical benefit or toxicity.  Analysis of ORR by tumor 
grade was not pre-specified. The secondary objectives were to estimate 
progression-free survival (PFS), overall survival (OS), ORR by immune-related 
RECIST (iRECIST), PFS by iRECIST, and to assess toxicity. 
PFS was measured from the start of protocol therapy to the first date of 
progression by RECIST v1.1 or death by any cause, with patients last known to be 
alive without progression censored at the date of last contact.  OS was measured 
from the date of study registration to the date of death by any cause, with patients 
last known to be alive censored at the date of last contact.  PFS and OS estimates 
were calculated using the Kaplan-Meier method and compared using log-rank tests.
Confidence intervals for medians were constructed using the method of 
Brookmeyer and Crowley (4), and confidence intervals (CI) for point estimates (e.g. 
6-month PFS) were calculated using the log-log transformation. CIs for the primary 
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ORR analysis accounted for the two-stage design (5); exact binomial CIs were 
calculated for subgroups utilizing the R function ‘get_CI’ from the package 
OneArmPhaseTwoStudy. Fisher’s exact test was used to compare subgroups.  All 
analyses were performed using R version 3.4.3.
RESULTS
Patient Characteristics 
Thirty-five patients from 22 National Clinical Trial Network (NCTN) institutions 
were registered between 4/13/2017-5/25/2018, with 32 patients meeting eligibility 
criteria and receiving protocol therapy who are summarized in (Table 1).  Three 
patients were excluded from analyses: two who were ineligible one of whom had an
ineligible histology, and the other with an inadequate washout period prior to 
treatment initiation; and one eligible patient refused protocol treatment after giving
initial consent. Of the 32 eligible patients who received protocol therapy, the 
median age was 60 years (range 36-81). The most common sites of primary tumor 
were lung and small intestine (both n=6). Notably, 18 of the 32 patients (56%) had 
high-grade carcinoma. The median number of prior lines of therapy was 2 for both 
the entire cohort as well as for patients with high-grade disease.
Toxicities
Treatment-related adverse events are summarized in Table 2, with 84.4% of 
patients experiencing an adverse event (AE), and 50% developing a grade 3-4 AE. 
The most common AEs (across all grades and at least possibly related to treatment)
were hypothyroidism (31%), fatigue (28%), nausea (28%), vomiting (25%), 
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aspartate aminotransferase (AST) increase (25%), alkaline phosphatase increase 
(22%) and anorexia (22%). Six patients experienced Grade 4 events, two with 
sepsis (6%), two with increased lipase (6%), one with retinopathy (3%), and one 
with hyperglycemia (3%).  Overall, 72% of patients developed an immune-related 
AE (irAE) of any grade on treatment, with 38% (N= 10) developing grade 3-4 irAEs. 
The most common irAEs of any grade were hypothyroidism (31%) and AST increase
(25%).  The most common grade 3-4 irAEs were alanine aminotransferase (ALT) 
increase (9%) and AST increase, lipase increase, and encephalopathy (all 6%).  
There were no treatment-related deaths. 
Outcomes
Among 32 patients, the ORR was 25% (95%CI 13%-42%), with 3% (N= 1) of 
patients achieving CR and 22% (N= 7) attaining a PR (Table 3, Figure 1A).  
Altogether, 41% of patients had stable disease with 6% having stable disease >6 
months and responses ongoing (Figure 1D).  Response rates were similar 
regardless of organ of origin (Figure 1B).  High-grade neuroendocrine carcinoma 
was present in 56% of patients (N = 18); 31% of patients had intermediate-grade; 
and 12% had low-grade biology.  Within the high-grade neuroendocrine cohort, 44%
(95% CI 22%-69% of patients; N = 8) had an objective response, with no responses 
(95% CI 0%-23%) in the intermediate or low-grade tumors (Figure 1C) (p = 0.004 
for ORR in high- versus low/intermediate grade).  The overall 6-month PFS rate was 
31% (19%, 52%), with a 6-month PFS rate of 44% (27-75%) in high-grade disease 
versus 14% (4-52%) in low-grade disease.  The median PFS is 4 months 95% CI (3, 
6) with ongoing responses (Appendix Figure 1) and the median OS is 11 months 
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95% CI (6,∞¿  (Appendix Figure 2). 
We also assessed patients with iRECIST.  There was only one patient that 
differed significantly.  This patient had intermediate-grade disease of small 
intestine origin and achieved a confirmed iPR (instead of progressive disease per 
RECIST v1.1). By RECIST v1.1 this patient had progressed 59 days after treatment 
initiation, but currently remains on study with clinical benefit 326+ days after 
treatment initiation with confirmed iPR.
DISCUSSION
Neuroendocrine neoplasms represent a histologically and molecularly 
heterogeneous constellation of rare cancers that can arise across various organ 
types.  Low- and intermediate-grade well-differentiated neuroendocrine neoplasms 
overexpress somatostatin receptors, which can be utilized both for functional 
imaging as well as therapeutic targeting with long-acting somatostatin analogs (6). 
In contrast, high-grade neuroendocrine carcinomas typically have more aggressive 
biology and minimal expression of somatostatin receptors and are typically treated 
with chemotherapy (7).  177Lu-Dotatate has recently shown activity with an 18% 
response rate for somatostatin-positive (low/intermediate grade) midgut 
neuroendocrine tumors and has attained Food and Drug Administration approval
(8). 
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To date, immune checkpoint blockade with anti-CTLA-4 and anti-PD-1 has not 
been prospectively studied broadly across rare tumors, or in combination for 
neuroendocrine neoplasms. Prior studies of anti-PD-1 directed monotherapy have 
had limited efficacy across the spectrum of neuroendocrine neoplasms (9),(10),
(11),(12),(13).  For this trial, the combination of ipilimumab with nivolumab was 
chosen to maximize response rates in signal finding cohorts relative to 
monotherapy, and the dose of ipilimumab of 1mg/kg IV every 6 weeks was chosen 
to minimize toxicity while retaining combinatorial efficacy based on published 
comparative data in other tumor types (14).  In the non-pancreatic neuroendocrine 
cohort of S1609 reported here, 25% of patients had a response to ipilimumab plus 
nivolumab, with no difference in ORR relative to organ of origin in our small cohort 
with a myriad of primary sites of origin (Figure 1B).  None of the lung tumors in 
our cohort were small-cell lung cancer, for which anti-PD-1 and anti-CTLA-4 have 
previously been investigated (15),(16),(17).  Of note, 44% of patients with high-
grade neuroendocrine carcinomas had an objective response to therapy (Figure 2).
Overall, this regimen resulted in no grade 5 toxicities, a <10% rate of grade 3-4 
immune-related colitis and hepatitis, and no reported pneumonitis in this cohort.  
However, serious treatment-related toxicity occurred in 37.5% of patients and 
treatment discontinuation due to grade 3-4 toxicities occurred in 31.5% of patients.
With responses across different primary tumor sites and a signal towards 
improved response in high-grade neuroendocrine carcinomas, a potential predictive
biomarker to help select for patients who may derive preferential benefit from 
immune checkpoint blockade is crucial.  Biomarker analyses are underway for 
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patients in the neuroendocrine cohort with a focus on PD-L1 expression by 
immunohistochemistry, tumor mutational burden, and comprehensive 
transcriptomic profiling given relevance in other tumor types (18),(19).  One prior 
study found that high-grade gastroenteropancreatic neuroendocrine carcinomas 
had a higher rate of PD-L1 expression relative to lower-grade tumors, and was 
associated with poorer survival(20).  Poorly-differentiated neuroendocrine 
carcinoma may also have a higher mutational burden than lower-grade 
tumors(21,22).  Clinically, anecdotal response to anti-PD-1 has been reported in 
high-mutational burden neuroendocrine carcinoma previously (23).  
Additionally, PD-L1 by IHC and tumor mutational burden in both tissue and 
blood have been associated with improved response to anti-PD-1 therapy across 
tumor types(18),(24,25),(26).  Host factors related to HLA-type, immune status, 
microbiome and underlying etiology likely play a key role in influencing response to 
immune checkpoint blockade.  To better understand the potential molecular basis 
for immunotherapeutic response, we assessed TMB and PD-L1 IHC in an 
independent cohort of neuroendocrine neoplasms not from S1609.  While PD-L1 IHC
was not different in high-grade versus intermediate/low-grade tumors, high-grade 
neuroendocrine tumors had a significantly greater rate of high TMB relative to 
intermediate/low-grade tumors, independent of site of origin (Appendix Table 2).  
Thus, TMB merits additional evaluation as a biomarker to potentially discriminate 
response to combinatorial immune checkpoint blockade, which will be specifically 
assayed in this cohort through whole-exome sequencing.  Overexpression of PD-L1 
in high-grade neuroendocrine carcinomas of the lung has also been reported (27).  
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The TMB landscape in large cell neuroendocrine tumor of lung (n=353) had been 
previously investigated and the median TMB found to be higher than in small cell 
lung cancer and non-small cell lung cancer (28). 
Strengths of this study include a broad population of patients across various 
tumor types representing both academic and community site accrual across the US,
and support from the NCI, SWOG, and patient advocacy groups.  Weaknesses of 
this study include its non-randomized nature, small sample size, and heterogenous 
patient population, which limit outcome comparisons between subgroups.  
Additionally, central pathology review was not mandated, and grading of tumor was
done locally and most often with Ki67 measurement.  Local pathology and imaging 
response assessments were utilized.  
As studied in SWOG 1609, a basket rare tumor immunotherapy trial, 
ipilimumab plus nivolumab has clinical activity in non-pancreatic neuroendocrine 
neoplasms, in particular high-grade neuroendocrine carcinomas, across numerous 
primary originating organ sites.  Ongoing studies focused on high-grade 
neuroendocrine carcinoma with rigorous correlative science to better understand 
host and tumor characteristics of immunotherapeutic response are underway.
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Table 1. Patient Characteristics (Median (min, max) or N (%) reported; 
N=32 patients).
Asterisks (*) denotes primary sites 
included in the GI (non-pancreatic) cohort
Table 2. Adverse Events at Least 
Possibly Related to Treatment (n=32
patients)
Any Grade
Treatment Related
Any 27
Serious 12
Led to discontinuation 10
Led to death 0
Occurred in ≥5% of patients
Fatigue 9
Nausea 9
Vomiting 8
Alkaline phosphatase 
increased 7
Anorexia 7
Lymphocyte count 
decreased 5
Platelet count decreased 5
Anemia 4
Dyspnea 4
Generalized muscle 
weakness 4
Weight loss 4
Hyperglycemia 3
Dizziness 3
Dry skin 3
17
Hypoalbuminemia 3 9.4% 0 0.0%
Neutrophil count 
decreased 3 9.4% 0 0.0%
White blood cell 
decreased 3 9.4% 0 0.0%
Autoimmune disorder 2 6.3% 2 6.3%
Sepsis 2 6.3% 2 6.3%
Acute kidney injury 2 6.3% 1 3.1%
Endocrine disorders-
Other 2 6.3% 1 3.1%
Sinusitis 2 6.3% 1 3.1%
Blurred vision 2 6.3% 0 0.0%
Constipation 2 6.3% 0 0.0%
Dry mouth 2 6.3% 0 0.0%
Dysgeusia 2 6.3% 0 0.0%
Edema limbs 2 6.3% 0 0.0%
Fever 2 6.3% 0 0.0%
Hypertension 2 6.3% 0 0.0%
Hypocalcemia 2 6.3% 0 0.0%
Hypokalemia 2 6.3% 0 0.0%
Proteinuria 2 6.3% 0 0.0%
Skin/subq tissue ds-
Other 2 6.3% 0 0.0%
Immune-mediated
Any 23 71.9% 12 37.5%
Hypothyroidism 10 31.3% 0 0.0%
AST increased 8 25.0% 2 6.3%
Arthralgia 7 21.9% 1 3.1%
Diarrhea 7 21.9% 1 3.1%
Pruritus 7 21.9% 0 0.0%
Rash maculo-papular 5 15.6% 1 3.1%
ALT increased 4 12.5% 3 9.4%
Lipase increased 3 9.4% 2 6.3%
Hyperthyroidism 3 9.4% 0 0.0%
Infusion related reaction 3 9.4% 0 0.0%
Encephalopathy 2 6.3% 2 6.3%
Colitis 2 6.3% 1 3.1%
Pancreatitis 2 6.3% 1 3.1%
Retinopathy 1 3.1% 1 3.1%
Blood bilirubin increased 1 3.1% 0 0.0%
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Table 3: Best Response Summary in 32 Patients with Neuroendocrine 
Neoplasms
Response type
All patients 
(n=32)
N(%)
High-grade 
(n=18)
N (%)
Low/
Intermediate 
grade (n=14)
N(%)
CR* 1 (3) 1 (6) 0 (0)
PR 7 (22) 7 (39) 0 (0)
SD > 6 months 2 (6) 0 (0) 2 (14)
SD ≤ 6 months 11 (34) 3 (17) 8 (57)
PD 11 (34) 7 (39) 4 (29)
CR + PR  8 (25) 8 (44) 0 (0)
CR + PR + SD > 6 
months
 10 (31) 8 (44) 2 (14)
*Unconfirmed CR after confirmed PR
Abbreviations:  CR = complete response; PR = partial response; SD = stable 
disease
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Figure 1.  Waterfall and Swimmer’s plots of tumor measurements. Gray 
lines at -30% and 20% indicate lines for partial response and progression per 
RECIST 1.1, respectively. Asterisk (*) and hatched bars in waterfall plots indicate 
patients who had early clinical progression (N = 3) or new lesions without 
assessable RECIST changes (N = 5; includes one patient who had new lesions on 
day 59, but currently remains on study with clinical benefit 326+ days after 
treatment initiation with confirmed iPR); these patients are shown as 21% increase 
indicating progression.  A) Overall waterfall plot;  B)  Waterfall plot by primary site;  
C) Waterfall plot by tumor grade; D) Swimmer’s plot by tumor grade
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